Alisporivir
- Generic Name
- Alisporivir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C63H113N11O12
- CAS Number
- 254435-95-5
- Unique Ingredient Identifier
- VBP9099AA6
- Background
Alisporivir has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C.
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 26
- Registration Number
- NCT04608214
- Locations
- 🇫🇷
Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 723
- Registration Number
- NCT02753699
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 52
- Registration Number
- NCT02094443
- Locations
- 🇫🇷
Novartis Investigative Site, Paris, France
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 16
- Registration Number
- NCT01975337
- Locations
- 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 147
- Registration Number
- NCT01970904
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 32
- Registration Number
- NCT01860326
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 6
- Registration Number
- NCT01500772
- Locations
- 🇩🇪
Novartis Investigational Site, Mainz, Germany
🇬🇧Novartis Investigative Site, London, United Kingdom
🇺🇸Novartis Investigational site, Bradenton, Florida, United States
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 8
- Registration Number
- NCT01446250
- Locations
- 🇺🇸
Novartis Investigational Site, Baltimore, Maryland, United States
Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
- Conditions
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 1081
- Registration Number
- NCT01318694
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 340
- Registration Number
- NCT01215643
- Locations
- 🇺🇸
The North Texas Research Institute, Arlington, Texas, United States
🇺🇸Saint Louis University, St. Louis, Missouri, United States
🇺🇸Liver Associates of Texas, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.